Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 12/20 | 0.68 |
| ▸ | CHRNA4 | P43681 | 12/20 | 0.68 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10153424 | 1.00 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3HRH4 | |
| SCHEMBL24028246 | 1.00 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3HRH4 | |
| Hydrochloric Acid SCHEMBL30261864 | 0.98 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3HRH4 | |
| SCHEMBL22015435 | 0.84 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL21963806 | 0.84 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5490131 | 0.82 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2962145 | 0.82 | CHRNB2 (0.84) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5988489 | 0.82 | CHRNB2 (0.84) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2958303 | 0.82 | CHRNB2 (0.84) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2962585 | 0.82 | CHRNB2 (0.84) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12329755-B2 | Bromodomain inhibitors to target therapy-resistant cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240316043-A1 | BROMODOMAIN INHIBITORS FOR CANCER THERAPY | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-09-26 | — | — | US | disclosed |
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2023-07-06 | — | — | US | disclosed |
| EP-4149939-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | Bristol-Myers Squibb Company (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20220296592-A1 | BROMODOMAIN INHIBITORS TO TARGET THERAPY-RESISTANT CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2022-09-22 | — | — | US | disclosed |
| US-20220296592-A1 | BROMODOMAIN INHIBITORS TO TARGET THERAPY-RESISTANT CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2022-09-22 | — | — | US | disclosed |
| WO-2021231243-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | CHRNB2 3418/4885CHRNA4 4429/4885CHRNB4 3950/4885 |
| US-20220296592-A1 | BROMODOMAIN INHIBITORS TO TARGET THERAPY-RESISTANT CANCER | BRD1, SMARCE1, SMARCA1 | CHRNB2 1076/4885CHRNA4 976/4885CHRNB4 1124/4885 |
| US-20240316043-A1 | BROMODOMAIN INHIBITORS FOR CANCER THERAPY | BRDT, BRD4, BRD3 | CHRNB2 2998/4885CHRNA4 3329/4885CHRNB4 3365/4885 |
| US-12329755-B2 | Bromodomain inhibitors to target therapy-resistant cancer | BRD1, SMARCE1, SMARCA1 | CHRNB2 1076/4885CHRNA4 976/4885CHRNB4 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.